Equities

Flora Growth Corp

FLGC:NAQ

Flora Growth Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.12
  • Today's Change-0.07 / -5.88%
  • Shares traded92.35k
  • 1 Year change-77.05%
  • Beta--
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Flora Growth Corp. is a cannabis company that manufactures and distributes consumer packaged goods and distributes medicinal cannabis and pharmaceutical product. Its brand consists of JustCBD, Vessel, No Cap Hemp Co., and Australian Vaporizers. JustCBD is a consumer-packaged goods brand with over 300 products, including cannabidiol gummies, topicals, tinctures, and vape products. JustCBD products are available for purchase in smoke and vape shops, clinics, spas, and pet stores, as well as other independent non-traditional retail channels. Vessel is the cannabis accessory and technology brand servicing the United States and Canada through direct-to-consumer and retail sales. Vessel's products include cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herb categories, which are sold to consumers, dispensaries, smoke shops, and cannabis brands. Australian Vaporizers is an online retailer of vaporizers, hardware, and accessories in Australia.

  • Revenue in USD (TTM)74.78m
  • Net income in USD-47.58m
  • Incorporated2019
  • Employees97.00
  • Location
    Flora Growth Corp3230 W. Commercial Boulevard, Suite 180FORT LAUDERDALE 33309United StatesUSA
  • Phone+1 (416) 861-2267
  • Websitehttps://www.floragrowth.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
FLGC:NAQ since
announced
Transaction
value
Australian Vaporizers Pty LtdDeal withdrawn18 Sep 202318 Sep 2023Deal withdrawn-59.86%1.90m
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mannatech Inc127.23m-1.66m14.14m213.00--1.35--0.1111-0.899-0.89968.075.542.771.93561.74597,342.80-3.624.39-9.679.1678.0177.87-1.311.720.5584--0.138488.33-3.83-5.3350.13---20.38--
Vicapsys Life Sciences Inc0.00-1.08m14.24m2.00---------0.0327-0.03270.00-0.04160.00----0.00-364.66-----------------10.40---------317.25------
Organovo Holdings Inc242.00k-19.09m14.30m15.00--1.58--59.09-2.17-2.170.02750.62830.0143--4.4412,100.00-112.40-51.24-123.59-54.90-----7,886.36-1,269.78----0.00---75.33-39.60-50.76--5.99--
Galecto Inc0.00-30.83m14.51m13.00--0.5151-----1.15-1.150.001.040.00----0.00-63.50-48.46-78.33-52.36------------0.00------37.77------
Edesa Biotech Inc0.00-7.25m14.76m16.00--3.41-----2.37-2.370.001.340.00----0.00-84.50---107.87--------------0.00------52.28------
Tonix Pharmaceuticals Holding Corp10.25m-98.59m14.77m103.00--0.1054--1.44-5.54-5.540.29561.470.0652----99,514.56-62.71-59.46-70.20-65.9237.55---961.87-5,126.730.8666--0.0767------0.1874--320.57--
Oncotelic Therapeutics Inc70.00k-7.79m14.79m22.00--1.25--211.26-0.0197-0.01970.00020.02960.0021--3.613,181.82-24.46-25.03-49.25-48.76-----11,536.00-1,692.93---0.46960.5341-------255.12------
Plus Therapeutics Inc (USA)6.08m-11.77m14.83m20.00------2.44-3.19-3.191.67-1.130.5724----304,200.00-110.75-59.18---133.04-----193.49-470.45--------2,093.30-5.8934.32--3.77--
Flora Growth Corp74.78m-47.58m14.87m97.00--3.32--0.1988-6.53-7.779.200.34941.485.9923.05770,958.80-92.50---140.01--21.72---62.66--0.6481--0.4952--127.75---1.87------
Traws Pharma Inc226.00k-18.16m15.04m16.00--2.08--66.53-0.8641-0.86410.01080.28530.0085--12.9114,125.00-68.21-63.43-104.99-85.72-----8,033.63-3,257.92----0.00--0.00-28.720.0844------
Nascent Biotech Inc0.00-2.09m15.28m----500.02-----0.0147-0.01470.000.00020.00-------346.80-815.53-----------548.75----0.8045---100.00---495.46------
Akari Therapeutics PLC (ADR)-100.00bn-100.00bn15.29m9.00---------------0.4449-----------149.95---435.18--------------------43.61------
Data as of Jun 07 2024. Currency figures normalised to Flora Growth Corp's reporting currency: US Dollar USD

Institutional shareholders

2.77%Per cent of shares held by top holders
HolderShares% Held
Amundi Asset Management US, Inc.as of 31 Mar 2024100.00k0.78%
Renaissance Technologies LLCas of 31 Mar 202477.61k0.61%
BofA Securities, Inc.as of 31 Mar 202472.60k0.57%
Geode Capital Management LLCas of 31 Mar 202440.09k0.31%
The Vanguard Group, Inc.as of 31 Mar 202423.06k0.18%
HRT Financial LLCas of 31 Mar 202416.33k0.13%
Two Sigma Securities LLCas of 31 Mar 202415.11k0.12%
Tower Research Capital LLCas of 31 Mar 20245.40k0.04%
VIMA LLCas of 31 Mar 20243.97k0.03%
RBC Dominion Securities, Inc. (Investment Management)as of 31 Mar 2024749.000.01%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.